Goetze S, van Drogen A, Albinus J, Fort K, Gandhi T, Robbiani D
Clin Proteomics. 2024; 21(1):26.
PMID: 38565978
PMC: 10988896.
DOI: 10.1186/s12014-024-09478-5.
Bunne C, Stark S, Gut G, Del Castillo J, Levesque M, Lehmann K
Nat Methods. 2023; 20(11):1759-1768.
PMID: 37770709
PMC: 10630137.
DOI: 10.1038/s41592-023-01969-x.
Langenbach M, Giesler S, Richtsfeld S, Costa-Pereira S, Rindlisbacher L, Wertheimer T
Mol Cancer Res. 2023; 21(8):849-864.
PMID: 37071397
PMC: 10524444.
DOI: 10.1158/1541-7786.MCR-22-0898.
Restivo G, Tastanova A, Balazs Z, Panebianco F, Diepenbruck M, Ercan C
Commun Biol. 2022; 5(1):1144.
PMID: 36307545
PMC: 9616892.
DOI: 10.1038/s42003-022-04025-0.
Amweg A, Tusup M, Cheng P, Picardi E, Dummer R, Levesque M
RNA Biol. 2022; 19(1):996-1006.
PMID: 35993275
PMC: 9415457.
DOI: 10.1080/15476286.2022.2110390.
Mesenchymal-Stromal Cell-like Melanoma-Associated Fibroblasts Increase IL-10 Production by Macrophages in a Cyclooxygenase/Indoleamine 2,3-Dioxygenase-Dependent Manner.
Cakir U, Hajdara A, Szeky B, Mayer B, Karpati S, Mezey E
Cancers (Basel). 2021; 13(24).
PMID: 34944793
PMC: 8699649.
DOI: 10.3390/cancers13246173.
Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression.
Saltari A, Dzung A, Quadri M, Tiso N, Facchinello N, Hernandez-Barranco A
Cancer Res. 2021; 81(23):6044-6057.
PMID: 34645608
PMC: 9397645.
DOI: 10.1158/0008-5472.CAN-21-0117.
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation.
Campbell N, Rao A, Hunter M, Sznurkowska M, Briker L, Zhang M
Dev Cell. 2021; 56(20):2808-2825.e10.
PMID: 34529939
PMC: 8551056.
DOI: 10.1016/j.devcel.2021.08.018.
Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4.
Diener J, Baggiolini A, Pernebrink M, Dalcher D, Lerra L, Cheng P
Nat Commun. 2021; 12(1):5056.
PMID: 34417458
PMC: 8379183.
DOI: 10.1038/s41467-021-25326-8.
Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma.
Tusup M, Cheng P, Picardi E, Raziunaite A, Dummer R, Levesque M
Noncoding RNA. 2021; 7(1).
PMID: 33445472
PMC: 7838980.
DOI: 10.3390/ncrna7010005.
Activation of RAS Signalling is Associated with Altered Cell Adhesion in Phaeochromocytoma.
Rossitti H, Dutta R, Larsson C, Ghayee H, Soderkvist P, Gimm O
Int J Mol Sci. 2020; 21(21).
PMID: 33138083
PMC: 7663737.
DOI: 10.3390/ijms21218072.
SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth.
Lazar I, Fabre B, Feng Y, Khateb A, Turko P, Martinez Gomez J
Mol Cancer Res. 2020; 18(10):1560-1573.
PMID: 32571981
PMC: 7541784.
DOI: 10.1158/1541-7786.MCR-20-0291.
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of -mutated Melanoma to MAPK Inhibitors.
Aloia A, Mullhaupt D, Chabbert C, Eberhart T, Fluckiger-Mangual S, Vukolic A
Clin Cancer Res. 2019; 25(22):6852-6867.
PMID: 31375515
PMC: 6906212.
DOI: 10.1158/1078-0432.CCR-19-0253.
Proteomic identification of a marker signature for MAPKi resistance in melanoma.
Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T
EMBO J. 2019; 38(15):e95874.
PMID: 31267558
PMC: 6669927.
DOI: 10.15252/embj.201695874.
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.
Florenes V, Flem-Karlsen K, McFadden E, Bergheim I, Nygaard V, Nygard V
Transl Oncol. 2019; 12(7):951-958.
PMID: 31096111
PMC: 6520638.
DOI: 10.1016/j.tranon.2019.04.001.
Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma.
Pozniak J, Nsengimana J, Laye J, OShea S, Diaz J, Droop A
Cancer Res. 2019; 79(10):2684-2696.
PMID: 30773503
PMC: 6544535.
DOI: 10.1158/0008-5472.CAN-18-2864.
VLA-4 mediated adhesion of melanoma cells on the blood-brain barrier is the critical cue for melanoma cell intercalation and barrier disruption.
Garcia-Martin A, Zwicky P, Gruber T, Matti C, Moalli F, Stein J
J Cereb Blood Flow Metab. 2018; 39(10):1995-2010.
PMID: 29762071
PMC: 6775593.
DOI: 10.1177/0271678X18775887.
low neurotrophin receptor CD271 regulates phenotype switching in melanoma.
Restivo G, Diener J, Cheng P, Kiowski G, Bonalli M, Biedermann T
Nat Commun. 2017; 8(1):1988.
PMID: 29215016
PMC: 5719420.
DOI: 10.1038/s41467-017-01573-6.
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers M, Widmer D, Narechania A, Eichhoff O, Freiberger S, Wenzina J
Oncotarget. 2016; 7(47):77163-77174.
PMID: 27791198
PMC: 5363577.
DOI: 10.18632/oncotarget.12848.
Explant culture of sarcoma patients' tissue.
Muff R, Botter S, Husmann K, Tchinda J, Selvam P, Seeli-Maduz F
Lab Invest. 2016; 96(7):752-62.
PMID: 27111283
DOI: 10.1038/labinvest.2016.49.